Semester of Graduation
First Major Professor
Dr. Jonathan Mochel
Master of Science (MS)
Chimeric antigen receptor (CAR) T-cell therapy is an emerging cancer treatment option throughout the world. This approach to cancer treatment uses a patient’s own immune cells and engineers them to directly target and kill cancer that has been evading their immune system. There has been much success when using CAR T-cell therapy in hematological malignancies due to the almost universal expression of the CD19 antigen. Though this success has not translated into success with solid tumors, there has been extensive research to improve the results. Solid tumors pose as a more difficult target due to their variable expression of target antigens, difficulty to penetrate, and hostile microenvironment. These challenges have been investigated and tested to improve CAR T-cell therapy success in the future.
Parris, Austin, "CAR T-Cell Therapy for Solid Tumors: How Far Are We from Reality?" (2019). Creative Components. 414.